Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

HLS Therapeutics TSE: HLS reported second-quarter fiscal 2026 revenue growth as its cardiovascular portfolio expanded 25% year over year, led by continued gains for Vascepa and the first full quarter of sales for newly launched NILEMDO.